“世界の次世代シーケンサー(NGS)市場は、2022年の130億米ドルから2027年には270億米ドルに達すると予測され、2022年から2027年の予測期間中の年平均成長率は15.7%”
癌研究における次世代シーケンサー(NGS)のアプリケーションの増加、癌の罹患率の増加、新しい次世代シーケンサー(NGS)プラットフォームと消耗品の発売は、次世代シーケンサー(NGS)市場の成長を促進すると予測されるいくつかの要因です。
消耗品セグメントが次世代シーケンサー(NGS)市場で最大シェアを占める 製品・サービス別に見ると、次世代シーケンサー(NGS)市場は次世代シーケンサー(NGS)消耗品、シーケンサーサービス、プレシーケンス製品・サービス、NGSプラットフォーム、NGSプラットフォーム向けサービス、バイオインフォマティクスに区分されます。2021年には、新しい試薬やキットの最近の発売、ゲノミクスの研究開発活動の増加により、NGS消耗品が最大のシェアを占めました。
“合成によるシーケンス分野が次世代シーケンサー(NGS)市場で最大シェアを占める”
次世代シーケンサー(NGS)市場は、技術別に、合成によるシーケンシング、イオン半導体シーケンシング、ナノポアシーケンシング、1分子リアルタイムシーケンシング、その他のシーケンシング技術に区分されます。2021年には、合成シーケンシング技術に基づく新しいNGSプラットフォームの発売により、合成シーケンシングセグメントがNGS市場で最大のシェアを獲得しました。
NGS市場の主要企業は、Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China). Other players in the market include Hamilton Company (US), MedGenome (US), Becton, Dickinson and Company (US), Genotypic Technology (India), and LGC Limited (US)などが含まれます。
“北米:次世代シーケンサー(NGS)市場で最大シェアを占める”
次世代シーケンサー(NGS)市場で最大のシェアを占めたのは北米です。研究資金の確保やNGSデータ解析ソリューションの開発などが市場成長の主な要因となります。
本レポートのために実施した一次インタビューは以下のように分類できます:
– 回答者別 供給側80%、需要側20%
– 役職別 管理職 – 45%、CXOおよびディレクターレベル – 30%、経営幹部 – 25%
– 地域別 北米 -20%、欧州 -10%、アジア太平洋地域 -55%、RoW -15%
レポート掲載企業リスト
• Illumina (US)
• Thermo Fisher Scientific (US)
• PerkinElmer (US)
• BGI Group (China)
• Agilent Technologies (US)
• Eurofins Scientific (Luxembourg)
• Pacific Biosciences (US)
• Oxford Nanopore Technologies (UK)
• QIAGEN (Netherlands)
• F. Hoffmann-La Roche AG (Switzerland)
• Brooks Automation (US)
• Psomagen, Inc. (US)
• 10x Genomics (US)
• Tecan Group (Switzerland)
• Zymo Research (US)
• Takara Bio (Japan)
• Promega Corporation (US)
• CD Genomics (US)
• New England Biolabs (US)
• Novogene Corporation (China)
• Hamilton Company (US)
• MedGenome (US)
• Becton, Dickinson and Company (US)
• Genotypic Technology (India)
• LGC Limited (US)
調査範囲
この調査レポートは、次世代シーケンサー(NGS)市場の詳細な状況を掲載しています。製品、用途、エンドユーザー、地域などさまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業プロフィールや最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主な利点
本レポートは、次世代シーケンサー(NGS)市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、より多くの洞察を得ることで、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートにより、関係者は市場動向を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を得ることができます。
8.5 OTHER APPLICATIONS 213
TABLE 230 NEXT-GENERATION SEQUENCING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 213
TABLE 231 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 213
TABLE 232 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 214
TABLE 233 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 214
TABLE 234 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 215
TABLE 235 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 215
9 NEXT-GENERATION SEQUENCING MARKET, BY END USER 216
9.1 INTRODUCTION 217
TABLE 236 NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 217
9.2 ACADEMIC INSTITUTES AND RESEARCH CENTERS 217
9.2.1 ACADEMIC AND RESEARCH INSTITUTES TO ACCOUNT FOR LARGEST MARKET SHARE 217
TABLE 237 NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC INSTITUTES AND RESEARCH CENTERS, BY REGION, 2020–2027 (USD MILLION) 218
TABLE 238 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC INSTITUTES AND RESEARCH CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 218
TABLE 239 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC INSTITUTES AND RESEARCH CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 219
TABLE 240 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC INSTITUTES AND RESEARCH CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 219
TABLE 241 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC INSTITUTES AND RESEARCH CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 220
TABLE 242 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR ACADEMIC INSTITUTES AND RESEARCH CENTERS, BY REGION, 2020–2027 (USD MILLION) 220
9.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 220
9.3.1 GROWING COLLABORATIONS BETWEEN NGS MARKET PLAYERS AND PHARMA-BIOTECH COMPANIES TO DRIVE GROWTH 220
TABLE 243 NEXT-GENERATION SEQUENCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 221
TABLE 244 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 221
TABLE 245 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 222
TABLE 246 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 222
TABLE 247 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 223
TABLE 248 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 223
9.4 HOSPITALS AND CLINICS 223
9.4.1 EXPANDING USE OF NGS IN HOSPITALS AND CLINICS TO BOOST GROWTH 223
TABLE 249 NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 224
TABLE 250 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 224
TABLE 251 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 225
TABLE 252 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 225
TABLE 253 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 226
TABLE 254 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 226
9.5 REFERENCE LABORATORIES 226
9.5.1 INCREASING AVAILABILITY OF TESTING SOLUTIONS AND HIGH ADOPTION OF NGS IN REFERENCE LABORATORIES TO DRIVE GROWTH 226
TABLE 255 NEXT-GENERATION SEQUENCING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 227
TABLE 256 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 227
TABLE 257 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 228
TABLE 258 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 228
TABLE 259 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 229
TABLE 260 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 229
9.6 OTHER END USERS 229
TABLE 261 NEXT-GENERATION SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 229
TABLE 262 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 230
TABLE 263 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 230
TABLE 264 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 231
TABLE 265 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 231
TABLE 266 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 231
10 NEXT-GENERATION SEQUENCING MARKET, BY REGION 232
10.1 INTRODUCTION 233
TABLE 267 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION) 233
10.2 NORTH AMERICA 234
FIGURE 30 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET SNAPSHOT 234
TABLE 268 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 235
TABLE 269 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 235
TABLE 270 NORTH AMERICA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 271 NORTH AMERICA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 272 NORTH AMERICA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 237
TABLE 273 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 237
TABLE 274 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 238
TABLE 275 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 276 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 277 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 239
10.2.1 US 240
10.2.1.1 Growing R&D activities in US to drive market growth 240
TABLE 278 US: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 241
TABLE 279 US: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 280 US: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 281 US: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 242
TABLE 282 US: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 243
TABLE 283 US: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 243
TABLE 284 US: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 285 US: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 286 US: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 245
10.2.2 CANADA 245
10.2.2.1 Increasing government initiatives in genomics research to boost adoption of NGS 245
TABLE 287 CANADA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 246
TABLE 288 CANADA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 289 CANADA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 290 CANADA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 291 CANADA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 248
TABLE 292 CANADA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 249
TABLE 293 CANADA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 294 CANADA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 250
TABLE 295 CANADA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 250
10.2.3 NORTH AMERICA: RECESSION IMPACT 251
10.3 EUROPE 251
TABLE 296 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 251
TABLE 297 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 252
TABLE 298 EUROPE: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 299 EUROPE: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 300 EUROPE: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 301 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 254
TABLE 302 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 254
TABLE 303 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 304 EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 305 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 256
10.3.1 GERMANY 256
10.3.1.1 Germany dominates European next-generation sequencing market 256
TABLE 306 GERMANY: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 257
TABLE 307 GERMANY: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 257
TABLE 308 GERMANY: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 309 GERMANY: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 310 GERMANY: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 258
TABLE 311 GERMANY: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 259
TABLE 312 GERMANY: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 313 GERMANY: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 260
TABLE 314 GERMANY: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 260
10.3.2 UK 261
10.3.2.1 Strategic initiatives and funding for genomics research to support adoption of NGS 261
TABLE 315 UK: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 262
TABLE 316 UK: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 317 UK: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 318 UK: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 319 UK: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 263
TABLE 320 UK: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 264
TABLE 321 UK: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 322 UK: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 323 UK: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 265
10.3.3 FRANCE 265
10.3.3.1 Government initiatives for genomics research to drive growth 265
TABLE 324 FRANCE: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 266
TABLE 325 FRANCE: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 266
TABLE 326 FRANCE: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 327 FRANCE: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 328 FRANCE: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 267
TABLE 329 FRANCE: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 268
TABLE 330 FRANCE: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 331 FRANCE: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 332 FRANCE: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 269
10.3.4 ITALY 269
10.3.4.1 Favorable funding scenario to drive adoption of next-generation sequencing 269
TABLE 333 ITALY: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 270
TABLE 334 ITALY: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 335 ITALY: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 336 ITALY: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 337 ITALY: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 271
TABLE 338 ITALY: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 272
TABLE 339 ITALY: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 340 ITALY: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 273
TABLE 341 ITALY: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 273
10.3.5 SPAIN 274
10.3.5.1 Focus on expanding genomic research to support growth 274
TABLE 342 SPAIN: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 274
TABLE 343 SPAIN: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 344 SPAIN: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 345 SPAIN: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 276
TABLE 346 SPAIN: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 276
TABLE 347 SPAIN: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 277
TABLE 348 SPAIN: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 349 SPAIN: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 350 SPAIN: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 278
10.3.6 NETHERLANDS 278
10.3.6.1 Focus on implementation of NGS to boost growth 278
TABLE 351 NETHERLANDS: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 279
TABLE 352 NETHERLANDS: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 279
TABLE 353 NETHERLANDS: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 354 NETHERLANDS: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 355 NETHERLANDS: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 280
TABLE 356 NETHERLANDS: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 281
TABLE 357 NETHERLANDS: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 358 NETHERLANDS: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 359 NETHERLANDS: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 282
10.3.7 REST OF EUROPE 282
TABLE 360 REST OF EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 283
TABLE 361 REST OF EUROPE: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 283
TABLE 362 REST OF EUROPE: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 363 REST OF EUROPE: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 364 REST OF EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 284
TABLE 365 REST OF EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 285
TABLE 366 REST OF EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 367 REST OF EUROPE: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 368 REST OF EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 286
10.3.8 EUROPE: RECESSION IMPACT 286
10.4 ASIA PACIFIC 287
FIGURE 31 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET SNAPSHOT 287
TABLE 369 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 288
TABLE 370 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 288
TABLE 371 ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 289
TABLE 372 ASIA PACIFIC: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 289
TABLE 373 ASIA PACIFIC: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 290
TABLE 374 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 290
TABLE 375 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 291
TABLE 376 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 291
TABLE 377 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 291
TABLE 378 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 292
10.4.1 CHINA 292
10.4.1.1 China to register highest growth in Asia Pacific market 292
TABLE 379 CHINA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 293
TABLE 380 CHINA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 293
TABLE 381 CHINA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 294
TABLE 382 CHINA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 294
TABLE 383 CHINA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 294
TABLE 384 CHINA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 295
TABLE 385 CHINA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 295
TABLE 386 CHINA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 296
TABLE 387 CHINA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 296
10.4.2 JAPAN 296
10.4.2.1 Rising number of collaborations for NGS to boost market growth 296
TABLE 388 JAPAN: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 297
TABLE 389 JAPAN: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 297
TABLE 390 JAPAN: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 298
TABLE 391 JAPAN: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 298
TABLE 392 JAPAN: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 298
TABLE 393 JAPAN: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 299
TABLE 394 JAPAN: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 299
TABLE 395 JAPAN: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 300
TABLE 396 JAPAN: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 300
10.4.3 INDIA 300
10.4.3.1 Government initiatives for genomics to support market growth 300
TABLE 397 INDIA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 301
TABLE 398 INDIA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 302
TABLE 399 INDIA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 302
TABLE 400 INDIA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 303
TABLE 401 INDIA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 303
TABLE 402 INDIA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 304
TABLE 403 INDIA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 304
TABLE 404 INDIA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 304
TABLE 405 INDIA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 305
10.4.4 AUSTRALIA 305
10.4.4.1 Increasing use of NGS platforms by academic institutes to propel market growth 305
TABLE 406 AUSTRALIA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 306
TABLE 407 AUSTRALIA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 306
TABLE 408 AUSTRALIA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 307
TABLE 409 AUSTRALIA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 307
TABLE 410 AUSTRALIA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 307
TABLE 411 AUSTRALIA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 308
TABLE 412 AUSTRALIA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 308
TABLE 413 AUSTRALIA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 308
TABLE 414 AUSTRALIA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 309
10.4.5 REST OF ASIA PACIFIC 309
TABLE 415 REST OF ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 310
TABLE 416 REST OF ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 310
TABLE 417 REST OF ASIA PACIFIC: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 311
TABLE 418 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 311
TABLE 419 REST OF ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 311
TABLE 420 REST OF ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 312
TABLE 421 REST OF ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 312
TABLE 422 REST OF ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 312
TABLE 423 REST OF ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 313
10.4.6 ASIA PACIFIC: RECESSION IMPACT 313
10.5 LATIN AMERICA 314
TABLE 424 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 314
TABLE 425 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 314
TABLE 426 LATIN AMERICA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 315
TABLE 427 LATIN AMERICA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 315
TABLE 428 LATIN AMERICA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 316
TABLE 429 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 316
TABLE 430 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 317
TABLE 431 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 317
TABLE 432 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 317
TABLE 433 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 318
10.5.1 BRAZIL 318
10.5.1.1 Rising focus on clinical genomics to drive demand for NGS 318
TABLE 434 BRAZIL: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 319
TABLE 435 BRAZIL: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 319
TABLE 436 BRAZIL: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 320
TABLE 437 BRAZIL: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 320
TABLE 438 BRAZIL: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 320
TABLE 439 BRAZIL: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 321
TABLE 440 BRAZIL: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 321
TABLE 441 BRAZIL: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 321
TABLE 442 BRAZIL: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 322
10.5.2 MEXICO 322
10.5.2.1 Biotechnology infrastructure development to support market growth 322
TABLE 443 MEXICO: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 323
TABLE 444 MEXICO: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 323
TABLE 445 MEXICO: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 324
TABLE 446 MEXICO: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 324
TABLE 447 MEXICO: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 324
TABLE 448 MEXICO: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 325
TABLE 449 MEXICO: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 325
TABLE 450 MEXICO: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 325
TABLE 451 MEXICO: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 326
10.5.3 REST OF LATIN AMERICA 326
TABLE 452 REST OF LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 326
TABLE 453 REST OF LATIN AMERICA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 327
TABLE 454 REST OF LATIN AMERICA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 327
TABLE 455 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 328
TABLE 456 REST OF LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 328
TABLE 457 REST OF LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 329
TABLE 458 REST OF LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 329
TABLE 459 REST OF LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 329
TABLE 460 REST OF LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 330
10.5.4 LATIN AMERICA: RECESSION IMPACT 330
10.6 MIDDLE EAST & AFRICA 331
TABLE 461 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION) 331
TABLE 462 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 331
TABLE 463 MIDDLE EAST & AFRICA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 332
TABLE 464 MIDDLE EAST & AFRICA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 332
TABLE 465 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 333
TABLE 466 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 333
TABLE 467 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 334
TABLE 468 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 334
TABLE 469 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 334
TABLE 470 MIDDLE EAST & AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 335
10.6.1 MIDDLE EAST 335
10.6.1.1 Expansion by prominent players and launch of genomic initiatives to support growth 335
TABLE 471 MIDDLE EAST: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 336
TABLE 472 MIDDLE EAST: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 336
TABLE 473 MIDDLE EAST: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 337
TABLE 474 MIDDLE EAST: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 337
TABLE 475 MIDDLE EAST: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 337
TABLE 476 MIDDLE EAST: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 338
TABLE 477 MIDDLE EAST: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 338
TABLE 478 MIDDLE EAST: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 338
TABLE 479 MIDDLE EAST: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 339
10.6.2 AFRICA 339
10.6.2.1 Collaborations among market players and government bodies to boost growth 339
TABLE 480 AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 340
TABLE 481 AFRICA: SEQUENCING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 340
TABLE 482 AFRICA: PRE-SEQUENCING PRODUCTS & SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 341
TABLE 483 AFRICA: BIOINFORMATICS MARKET, BY TYPE, 2020–2027 (USD MILLION) 341
TABLE 484 AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 341
TABLE 485 AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 342
TABLE 486 AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 342
TABLE 487 AFRICA: NEXT-GENERATION SEQUENCING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 342
TABLE 488 AFRICA: NEXT-GENERATION SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 343
10.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT 343
11 COMPETITIVE LANDSCAPE 344
11.1 INTRODUCTION 344
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 345
FIGURE 32 NEXT-GENERATION SEQUENCING MARKET: STRATEGIES ADOPTED 345
11.3 REVENUE ANALYSIS 346
FIGURE 33 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 346
11.4 MARKET SHARE ANALYSIS 347
FIGURE 34 NEXT-GENERATION SEQUENCING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 347
TABLE 489 NEXT-GENERATION SEQUENCING MARKET: DEGREE OF COMPETITION 347
11.5 COMPANY EVALUATION MATRIX 349
11.5.1 STARS 349
11.5.2 EMERGING LEADERS 349
11.5.3 PERVASIVE PLAYERS 349
11.5.4 PARTICIPANTS 349
FIGURE 35 NEXT-GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX, 2021 350
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 351
11.6.1 OVERALL COMPANY FOOTPRINT (25 COMPANIES) 351
TABLE 490 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 351
11.6.2 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 352
TABLE 491 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 352
11.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 353
TABLE 492 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 353
11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 354
11.7.1 PROGRESSIVE COMPANIES 354
11.7.2 STARTING BLOCKS 354
11.7.3 RESPONSIVE COMPANIES 354
11.7.4 DYNAMIC COMPANIES 354
FIGURE 36 NEXT-GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 355
11.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 356
TABLE 493 NEXT-GENERATION SEQUENCING MARKET: DETAILED LIST OF KEY START-UPS/SMES 356
TABLE 494 NEXT-GENERATION SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 357
11.9 COMPETITIVE SCENARIO AND TRENDS 358
11.9.1 PRODUCT LAUNCHES 358
TABLE 495 NEXT-GENERATION SEQUENCING MARKET: KEY PRODUCT LAUNCHES, JANUARY 2019–DECEMBER 2022 358
11.9.2 DEALS 358
TABLE 496 NEXT-GENERATION SEQUENCING MARKET: KEY DEALS, JANUARY 2019–DECEMBER 2022 358
11.9.3 OTHER DEVELOPMENTS 359
TABLE 497 NEXT-GENERATION SEQUENCING MARKET: OTHER KEY DEVELOPMENTS, JANUARY 2019–DECEMBER 2022 359
12 COMPANY PROFILES 360
12.1 KEY PLAYERS 360
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ILLUMINA, INC. 360
TABLE 498 ILLUMINA, INC.: BUSINESS OVERVIEW 360
FIGURE 37 ILLUMINA, INC.: COMPANY SNAPSHOT (2021) 361
12.1.2 THERMO FISHER SCIENTIFIC, INC. 370
TABLE 499 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 370
FIGURE 38 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 371
12.1.3 PERKINELMER 381
TABLE 500 PERKINELMER: BUSINESS OVERVIEW 381
FIGURE 39 PERKINELMER: COMPANY SNAPSHOT (2021) 382
12.1.4 AGILENT TECHNOLOGIES, INC. 386
TABLE 501 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 386
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 387
12.1.5 PACIFIC BIOSCIENCES 391
TABLE 502 PACIFIC BIOSCIENCES: BUSINESS OVERVIEW 391
FIGURE 41 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2021) 392
12.1.6 OXFORD NANOPORE TECHNOLOGIES 397
TABLE 503 OXFORD NANOPORE TECHNOLOGIES: BUSINESS OVERVIEW 397
FIGURE 42 OXFORD NANOPORE TECHNOLOGIES: COMPANY SNAPSHOT (2021) 398
12.1.7 BGI GROUP 404
TABLE 504 BGI GROUP: BUSINESS OVERVIEW 404
12.1.8 QIAGEN 411
TABLE 505 QIAGEN: BUSINESS OVERVIEW 411
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2021) 412
12.1.9 F. HOFFMANN-LA ROCHE AG 421
TABLE 506 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 421
FIGURE 44 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 422
12.1.10 EUROFINS SCIENTIFIC 426
TABLE 507 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 426
FIGURE 45 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 426
12.1.11 BROOKS AUTOMATION, INC. 429
TABLE 508 BROOKS AUTOMATION, INC.: BUSINESS OVERVIEW 429
FIGURE 46 BROOKS AUTOMATION, INC.: COMPANY SNAPSHOT (2021) 430
12.1.12 PSOMAGEN 432
TABLE 509 PSOMAGEN: BUSINESS OVERVIEW 432
12.1.13 10X GENOMICS 434
TABLE 510 10X GENOMICS: BUSINESS OVERVIEW 434
12.1.14 TECAN TRADING GROUP 437
TABLE 511 TECAN TRADING GROUP: BUSINESS OVERVIEW 437
FIGURE 47 TECAN GROUP: COMPANY SNAPSHOT (2021) 438
12.1.15 ZYMO RESEARCH 440
TABLE 512 ZYMO RESEARCH: BUSINESS OVERVIEW 440
12.1.16 TAKARA BIO 442
TABLE 513 TAKARA BIO: BUSINESS OVERVIEW 442
FIGURE 48 TAKARA BIO: COMPANY SNAPSHOT (2021) 443
12.1.17 PROMEGA CORPORATION 446
TABLE 514 PROMEGA CORPORATION: BUSINESS OVERVIEW 446
12.1.18 CD GENOMICS 449
TABLE 515 CD GENOMICS: BUSINESS OVERVIEW 449
12.1.19 NEW ENGLAND BIOLABS 454
TABLE 516 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW 454
12.1.20 NOVOGENE CORPORATION INC. 460
TABLE 517 NOVOGENE CORPORATION INC.: BUSINESS OVERVIEW 460
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER COMPANIES 463
12.2.1 HAMILTON COMPANY 463
12.2.2 MEDGENOME 464
12.2.3 BECTON, DICKINSON AND COMPANY 465
12.2.4 COSMOSID, INC. 466
12.2.5 GENOTYPIC TECHNOLOGY 467
12.2.6 LGC LIMITED 468
13 APPENDIX 469
13.1 DISCUSSION GUIDE 469
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 474
13.3 CUSTOMIZATION OPTIONS 476
13.4 RELATED REPORTS 476
13.5 AUTHOR DETAILS 477
*** 免責事項 ***https://www.globalresearch.co.jp/disclaimer/